To include your compound in the COVID-19 Resource Center, submit it here.

Going with the flow

Canaan prepares to invest 30% of its $800M fund in biopharma

As early stage VC rounds continue to grow, Canaan Partners is once again planning to bump up its allocation to biopharma with its new $800 million fund.

Nearly a third of Canaan XI, which closed on

Read the full 361 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers